search
Back to results

Digital Life Coaching for Myeloma Patients Undergoing Transplantation

Primary Purpose

Multiple Myeloma

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Pack Health's digital life coaching (DLC)
Sponsored by
University of California, San Francisco
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Multiple Myeloma focused on measuring Multiple Myeloma, Digital life coaching, Hematopoietic stem cell transplantation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Confirmed diagnosis of one of the following (all referred to as MM in this protocol):

    • Multiple myeloma (ICD-10 code: C90.0)
    • Extramedullary plasmacytoma (ICD-10 code: C90.2)
  • Planned receipt of autologous HCT at our institution

    • Patients undergoing outpatient HCT will be eligible
    • Patients who received chemomobilization will be eligible
  • Age ≥ 18, as life coaches employed by the DLC vendor are not currently trained to work with pediatric patients

Exclusion Criteria:

  • Prior autologous HCT for any indication
  • Physician-assessed lack of sufficient English proficiency
  • Lack of ownership of a personal smartphone
  • Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with participant's safety, provision of informed consent, or compliance with study procedures

Sites / Locations

  • University of California, San Francisco

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Pack Health's digital life coaching (DLC)

Arm Description

Access to the DLC platform during a 16-week period encompassing pre-HCT conditioning chemotherapy, post-HCT recovery, and 100-day follow-up

Outcomes

Primary Outcome Measures

Number of participants displaying ongoing engagement with DLC
Ongoing participant engagement is defined as at least 4 or more participant-initiated interactions with the DLC platform, including at least 1 interaction in each of four 4-week study sub-periods

Secondary Outcome Measures

Median PRO Measurement Information System (PROMIS) Global Health (GH) Score
The PROMIS GH instrument v1.2 will be used to assess quality of life. This 10-item inventory with scores ranging from 1 to 5 with higher scores indicating a a greater quality of life. Raw PROMIS scores will subsequently be transformed to T-score metrics as per the scoring manual to reflect a population mean of 50 and standard deviation of 10. Among cancer patients, a T-score change of 5 points on any PROMIS inventory is generally considered to be clinically meaningful.
Median National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT) Score
The NCCN DT will be used to assess psychosocial distress. This single-item inventory uses a graphic of a thermometer to allow patients to assess their overall distress on a scale of 0=No Distress to 10= Extreme distress. The NCCN considers a cutoff score of 4 to differentiate clinically significant distress.
Median PROMIS Sleep Disturbance (SD) Short Form (SF) 4a Score
The PROMIS SD SF 4a inventory will be used to measure overall sleep disturbance in past 7 days. This assessment consists of 4 items which measure sleep quality and sleep disturbances using a 5 point likert scale ranging in value from 1 to 5 with higher scores indicating greater sleep quality. Raw PROMIS scores will subsequently be transformed to T-score metrics as per the scoring manual to reflect a population mean of 50 and standard deviation of 10. Among cancer patients, a T-score change of 5 points on any PROMIS inventory is generally considered to be clinically meaningful
Median Participant Satisfaction Score
Participants will be asked to provide a response, on a scale from 0 (not at all likely) to 10 (extremely likely), to the following single question: "How likely are you to recommend this life coaching tool to other patients undergoing stem cell transplantation?"

Full Information

First Posted
June 11, 2020
Last Updated
June 1, 2021
Sponsor
University of California, San Francisco
search

1. Study Identification

Unique Protocol Identification Number
NCT04432818
Brief Title
Digital Life Coaching for Myeloma Patients Undergoing Transplantation
Official Title
Digital Life Coaching in Multiple Myeloma Patients Undergoing Hematopoietic Stem Cell Transplantation
Study Type
Interventional

2. Study Status

Record Verification Date
June 2021
Overall Recruitment Status
Completed
Study Start Date
May 20, 2020 (Actual)
Primary Completion Date
February 25, 2021 (Actual)
Study Completion Date
February 25, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is the first study of digital life coaching (DLC) to engage patients during the peri-HCT period that is punctuated by intensive life changes. DLC may circumvent these limitations by combining the integrative cross-dimensional nature of life coaching with the advantages of mobile health technology. The purpose of this study is to evaluate whether ongoing participant engagement with a DLC platform is feasible for multiple myeloma (MM) patients actively undergoing hematopoietic stem cell transplantation (HCT).
Detailed Description
Participants will receive unlimited access to Pack Health's DLC platform during a 16-week period encompassing pre-HCT conditioning chemotherapy, post-HCT recovery, and 100-day follow-up. Participants will engage with Pack Health's DLC platform and complete quality of life assessments for 16 weeks beginning from enrollment. At the conclusion of the treatment period, participants will be asked to rate their satisfaction with the DLC platform Primary Objective: To evaluate the rate of ongoing participant engagement with a DLC platform during the study period Secondary Objectives: To assess quality of life among participants during the study period To assess psychosocial distress among participants during the study period To assess sleep disturbances among participants during the study period To assess participant satisfaction with the DLC platform at the end of the study period Exploratory Objectives: To assess benzodiazepine and zolpidem-class drug usage for anxiety or insomnia among participants during the study period To assess communications with treatment teams among participants during the study period To assess 100-day clinical outcomes among participants at the end of the study period

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Myeloma
Keywords
Multiple Myeloma, Digital life coaching, Hematopoietic stem cell transplantation

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
17 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Pack Health's digital life coaching (DLC)
Arm Type
Experimental
Arm Description
Access to the DLC platform during a 16-week period encompassing pre-HCT conditioning chemotherapy, post-HCT recovery, and 100-day follow-up
Intervention Type
Behavioral
Intervention Name(s)
Pack Health's digital life coaching (DLC)
Intervention Description
Pack Health smartphone-based DLC platform will be provided for 16-week subscription which allows unlimited bidirectional communication between enrolled participants and their life coach
Primary Outcome Measure Information:
Title
Number of participants displaying ongoing engagement with DLC
Description
Ongoing participant engagement is defined as at least 4 or more participant-initiated interactions with the DLC platform, including at least 1 interaction in each of four 4-week study sub-periods
Time Frame
Up to 16 weeks
Secondary Outcome Measure Information:
Title
Median PRO Measurement Information System (PROMIS) Global Health (GH) Score
Description
The PROMIS GH instrument v1.2 will be used to assess quality of life. This 10-item inventory with scores ranging from 1 to 5 with higher scores indicating a a greater quality of life. Raw PROMIS scores will subsequently be transformed to T-score metrics as per the scoring manual to reflect a population mean of 50 and standard deviation of 10. Among cancer patients, a T-score change of 5 points on any PROMIS inventory is generally considered to be clinically meaningful.
Time Frame
Up to 16 weeks
Title
Median National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT) Score
Description
The NCCN DT will be used to assess psychosocial distress. This single-item inventory uses a graphic of a thermometer to allow patients to assess their overall distress on a scale of 0=No Distress to 10= Extreme distress. The NCCN considers a cutoff score of 4 to differentiate clinically significant distress.
Time Frame
Up to 16 weeks
Title
Median PROMIS Sleep Disturbance (SD) Short Form (SF) 4a Score
Description
The PROMIS SD SF 4a inventory will be used to measure overall sleep disturbance in past 7 days. This assessment consists of 4 items which measure sleep quality and sleep disturbances using a 5 point likert scale ranging in value from 1 to 5 with higher scores indicating greater sleep quality. Raw PROMIS scores will subsequently be transformed to T-score metrics as per the scoring manual to reflect a population mean of 50 and standard deviation of 10. Among cancer patients, a T-score change of 5 points on any PROMIS inventory is generally considered to be clinically meaningful
Time Frame
Up to 16 weeks
Title
Median Participant Satisfaction Score
Description
Participants will be asked to provide a response, on a scale from 0 (not at all likely) to 10 (extremely likely), to the following single question: "How likely are you to recommend this life coaching tool to other patients undergoing stem cell transplantation?"
Time Frame
Up to 16 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Confirmed diagnosis of one of the following (all referred to as MM in this protocol): Multiple myeloma (ICD-10 code: C90.0) Extramedullary plasmacytoma (ICD-10 code: C90.2) Planned receipt of autologous HCT at our institution Patients undergoing outpatient HCT will be eligible Patients who received chemomobilization will be eligible Age ≥ 18, as life coaches employed by the DLC vendor are not currently trained to work with pediatric patients Exclusion Criteria: Prior autologous HCT for any indication Physician-assessed lack of sufficient English proficiency Lack of ownership of a personal smartphone Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with participant's safety, provision of informed consent, or compliance with study procedures
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rahul Banerjee, MD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California, San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
35039279
Citation
Banerjee R, Huang CY, Dunn L, Knoche J, Ryan C, Brassil K, Jackson L, Patel D, Lo M, Arora S, Wong SW, Wolf J, Martin Iii T, Dhruva A, Shah N. Digital Life Coaching During Stem Cell Transplantation: Development and Usability Study. JMIR Form Res. 2022 Mar 4;6(3):e33701. doi: 10.2196/33701.
Results Reference
derived

Learn more about this trial

Digital Life Coaching for Myeloma Patients Undergoing Transplantation

We'll reach out to this number within 24 hrs